Is drug release necessary for antimicrobial activity of siderophore-drug conjugates? Syntheses and biological studies of the naturally occurring salmycin "Trojan Horse" antibiotics and synthetic desferridanoxamine-antibiotic conjugates
about
Siderophores; iron scavengers: the novel & promising targets for pathogen specific antifungal therapy.Biotrophy-specific downregulation of siderophore biosynthesis in Colletotrichum graminicola is required for modulation of immune responses of maizeAdvances in iron chelation: an update.Antimicrobial peptides from arachnid venoms and their microbicidal activity in the presence of commercial antibiotics.The 2012 Garrod lecture: discovery of antibacterial drugs in the 21st century.New Synthetic Approach for the Incorporation of 3,2-Hydroxypyridinone (HOPO) Ligands: Synthesis of Structurally Diverse Poly HOPO Chelators.Iron acquisition in the cystic fibrosis lung and potential for novel therapeutic strategies.Diverted Total Synthesis of Promysalin Analogs Demonstrates That an Iron-Binding Motif Is Responsible for Its Narrow-Spectrum Antibacterial ActivityChemical syntheses and in vitro antibacterial activity of two desferrioxamine B-ciprofloxacin conjugates with potential esterase and phosphatase triggered drug release linkers.Preparation of bifunctional isocyanate hydroxamate linkers: Synthesis of carbamate and urea tethered polyhydroxamic acid chelators.Trihydroxamate siderophore-fluoroquinolone conjugates are selective sideromycin antibiotics that target Staphylococcus aureus.Biscatecholate-monohydroxamate mixed ligand siderophore-carbacephalosporin conjugates are selective sideromycin antibiotics that target Acinetobacter baumanniiExploiting bacterial iron acquisition: siderophore conjugates.Microbial siderophores: a mini review.Siderophore-dependent iron uptake systems as gates for antibiotic Trojan horse strategies against Pseudomonas aeruginosa.Characterization of microbial siderophores by mass spectrometry.Microbial siderophore-based iron assimilation and therapeutic applications.Siderophores as molecular tools in medical and environmental applications.Tetracycline nanoparticles as antibacterial and gene-silencing agents.Bifunctional antimicrobial conjugates and hybrid antimicrobials.The Pseudomonas aeruginosa PA14 ABC Transporter NppA1A2BCD Is Required for Uptake of Peptidyl Nucleoside Antibiotics.Siderophore-fluoroquinolone conjugates containing potential reduction-triggered linkers for drug release: synthesis and antibacterial activity.Diphenyl-benzo[1,3]dioxole-4-carboxylic acid pentafluorophenyl ester: a convenient catechol precursor in the synthesis of siderophore vectors suitable for antibiotic Trojan horse strategies.TonB-Dependent Receptor Repertoire of Pseudomonas aeruginosa for Uptake of Siderophore-Drug Conjugates.Esterase-Catalyzed Siderophore Hydrolysis Activates an Enterobactin-Ciprofloxacin Conjugate and Confers Targeted Antibacterial Activity.d-Sedoheptulose-7-phosphate is a common precursor for the heptoses of septacidin and hygromycin B.Microcin C and albomycin analogues with aryl-tetrazole substituents as nucleobase isosters are selective inhibitors of bacterial aminoacyl tRNA synthetases but lack efficient uptake.Biological activity of synthetic ionophores: ion transporters as prospective drugs?
P2860
Q30243906-E4EF866F-EB66-4929-856C-E097BF4C93DBQ30317484-38181A58-D011-44FE-A2E1-51D982AE8920Q34174307-5D8FD6FF-6C20-438A-B826-8D5D5C55AC44Q34455853-5F1499EE-0FC1-4F6E-BABD-4111C6A11490Q34470233-5DF699AA-74F7-41E6-95C4-B6281D01AA64Q35060340-F468FCC6-E666-464B-8D96-51EFEF690163Q35862783-10534B05-BB4B-4188-A834-78D408763544Q35994688-89692243-8273-4A2E-8858-4C7C870ECBE2Q35998189-B3A113D5-D405-49D0-9C2F-294DDA566567Q36399691-284F7173-501A-47DE-9B97-6580DF065D5EQ36787714-83FDA6E3-878A-48B5-9A98-9FD97C9EC82FQ36949581-638F7BFB-C909-4B82-82DD-82ACC8AB4C48Q37990947-8F84E6FD-35D8-478A-93C5-C465C7909DADQ38021726-BD9C1958-BEA3-40B2-B6FF-DA8C7C22E397Q38183671-7A430EB9-4C5C-471A-8184-B5A419498C96Q38484539-6B312C05-1799-4B56-8A5C-C3220DDD6BE8Q38825854-0B837CEE-CDC5-4890-8163-173E9AF5D672Q38919129-E3434B00-EABF-4232-8D97-A192D6D34FEBQ38937736-C23467AE-38FA-431B-89EA-2E1572192109Q40203926-5D55C461-A0C1-4461-B936-6AA093F76261Q41007282-C34CE745-8C1A-4542-8388-49DC53BFBBE8Q49182019-8EAF0DEB-1EBC-4702-9976-DDE6E49D0305Q51768774-30FD90D2-984C-4253-B05B-1B8DC85E44FBQ52349917-8015B74E-5F2F-48FE-9487-EF26CA4E07DAQ53762102-61B78949-F684-454C-A3CF-470164DD5FC6Q54209175-7946B2DE-ED87-4C45-BDA9-0DDE9AAF429AQ54331234-C3BB0B68-696E-4CA1-9CE3-CBB88F7E2C2EQ58172250-2B4E1B67-C5C8-4DBF-81CE-78C301A5D297
P2860
Is drug release necessary for antimicrobial activity of siderophore-drug conjugates? Syntheses and biological studies of the naturally occurring salmycin "Trojan Horse" antibiotics and synthetic desferridanoxamine-antibiotic conjugates
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Is drug release necessary for ...... noxamine-antibiotic conjugates
@en
Is drug release necessary for ...... oxamine-antibiotic conjugates.
@nl
type
label
Is drug release necessary for ...... noxamine-antibiotic conjugates
@en
Is drug release necessary for ...... oxamine-antibiotic conjugates.
@nl
prefLabel
Is drug release necessary for ...... noxamine-antibiotic conjugates
@en
Is drug release necessary for ...... oxamine-antibiotic conjugates.
@nl
P2093
P2860
P1433
P1476
Is drug release necessary for ...... noxamine-antibiotic conjugates
@en
P2093
Marvin J Miller
Timothy A Wencewicz
Timothy E Long
P2860
P2888
P304
P356
10.1007/S10534-009-9218-3
P50
P577
2009-02-17T00:00:00Z